News

The American Journal of Managed Care1h
Guselkumab Clears Scalp Psoriasis Across All Skin Tones
A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...
Taiwan News3h
60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
Data from three independent clinical studies demonstrate utility of tafenoquine to treat acute canine babesiosis; WASHINGTON, July 14, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmace ...
LionhearTV10h
Chamber of Cosmetics Industry of the Philippines announces Cosmeticon Year 3: A deep dive into product safety assessment
The Chamber of Cosmetics Industry of the Philippines (CCIP) proudly announces the return of its highly anticipated annual event, Cosmeticon Year 3, scheduled this August 28th, 8am-5pm at the F1 Hotel, ...
Ophthalmology Times10h
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...
Medscape11h
Lurbinectedin Shows Modest Efficacy and Safety in Extensive-Stage Small Cell Lung Cancer
Compassionate-use lurbinectedin demonstrates modest yet consistent efficacy and is well tolerated in patients with ...
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...